KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regeneron Pharmaceuticals (REGN) Non-Current Assets (2016 - 2025)

Regeneron Pharmaceuticals (REGN) has 17 years of Non-Current Assets data on record, last reported at -$18.0 billion in Q4 2025.

  • For Q4 2025, Non-Current Assets fell 194.36% year-over-year to -$18.0 billion; the TTM value through Dec 2025 reached $45.5 billion, up 6196.74%, while the annual FY2025 figure was -$18.0 billion, 194.36% down from the prior year.
  • Non-Current Assets reached -$18.0 billion in Q4 2025 per REGN's latest filing, down from $22.2 billion in the prior quarter.
  • Across five years, Non-Current Assets topped out at $22.2 billion in Q3 2025 and bottomed at -$19.1 billion in Q2 2024.
  • Average Non-Current Assets over 5 years is $4.4 billion, with a median of $13.2 billion recorded in 2023.
  • Peak YoY movement for Non-Current Assets: tumbled 303.05% in 2021, then surged 211.94% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at -$13.8 billion in 2021, then skyrocketed by 196.77% to $13.3 billion in 2022, then increased by 2.03% to $13.6 billion in 2023, then soared by 40.42% to $19.1 billion in 2024, then plummeted by 194.36% to -$18.0 billion in 2025.
  • Per Business Quant database, its latest 3 readings for Non-Current Assets were -$18.0 billion in Q4 2025, $22.2 billion in Q3 2025, and $21.4 billion in Q2 2025.